Key Takeaways & Executive Findings
- β’β’ Correction of Figure 4 in the original paper on ITGA7 downregulation in papillary thyroid carcinoma. β’ The corrected figure shows cell migration assays and quantitative results, confirming the role of ITGA7 knockdown in promoting migration. β’ The corrigendum ensures accuracy of the published data for future research and clinical applications. β’ The study highlights ITGA7 as a potential therapeutic target in papillary thyroid carcinoma.
Abstract
This is a corrigendum to the original article published in Acta Biochim Biophys Sin 2020, 52(2): 116β124. The authors correct an error in Figure 4 of the original manuscript. The correct figure is provided, and the authors apologize for the error.
1. Introduction
This corrigendum addresses an error in the original article titled 'Downregulating integrin subunit alpha 7 (ITGA7) promotes proliferation, invasion, and migration of papillary thyroid carcinoma cells through regulating epithelial-to-mesenchymal transition' published in Acta Biochim Biophys Sin 2020, 52(2): 116β124. The authors identified an error in Figure 4 and provide the correct figure here.
The original study investigated the role of ITGA7 in papillary thyroid carcinoma (PTC), demonstrating that its downregulation promotes cell proliferation, invasion, and migration via epithelial-to-mesenchymal transition. The corrected Figure 4 presents the cell migration assays and quantitative results, confirming the findings.
Loading authentic research manuscript (Pages 1β5)...
Yaoyao Guan, Adheesh Bhandari, Erjie Xia, Lingguo Kong, Xiaohua Zhang, Ouchen Wang (2026). Corrigendum to: Downregulating integrin subunit alpha 7 (ITGA7) promotes proliferation, invasion, and migration of papillary thyroid carcinoma cells through regulating epithelial-to-mesenchymal transition. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2024200
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the purpose of this corrigendum?
The corrigendum corrects an error in Figure 4 of the original article, providing the correct figure to ensure the accuracy of the published data.
What was the error in the original article?
An error was found in Figure 4 of the original manuscript, which has been corrected in this corrigendum.
What is the role of ITGA7 in papillary thyroid carcinoma?
Downregulation of ITGA7 promotes proliferation, invasion, and migration of papillary thyroid carcinoma cells through regulating epithelial-to-mesenchymal transition.
Who are the authors of the original article?
The authors are Yaoyao Guan, Adheesh Bhandari, Erjie Xia, Lingguo Kong, Xiaohua Zhang, and Ouchen Wang.
Where was the original article published?
The original article was published in Acta Biochimica et Biophysica Sinica, 2020, volume 52, issue 2, pages 116β124.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.